These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21704746)
1. Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma. Ishihara T; Fukuda I; Morita A; Takinami Y; Okamoto H; Nishimura S; Numata Y J Proteomics; 2011 Sep; 74(10):2159-68. PubMed ID: 21704746 [TBL] [Abstract][Full Text] [Related]
2. Parallel reaction monitoring with multiplex immunoprecipitation of N-glycoproteins in human serum for detection of hepatocellular carcinoma. Kim KH; Park GW; Jeong JE; Ji ES; An HJ; Kim JY; Yoo JS Anal Bioanal Chem; 2019 May; 411(14):3009-3019. PubMed ID: 31076819 [TBL] [Abstract][Full Text] [Related]
3. A new versatile peptide-based size exclusion chromatography platform for global profiling and quantitation of candidate biomarkers in hepatocellular carcinoma specimens. Lee HJ; Na K; Kwon MS; Park T; Kim KS; Kim H; Paik YK Proteomics; 2011 May; 11(10):1976-84. PubMed ID: 21500349 [TBL] [Abstract][Full Text] [Related]
4. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Oh JH; Pan S; Zhang J; Gao J Rapid Commun Mass Spectrom; 2010 Feb; 24(4):403-8. PubMed ID: 20069694 [TBL] [Abstract][Full Text] [Related]
5. Abundance-ratio-based semiquantitative analysis of site-specific N-linked glycopeptides present in the plasma of hepatocellular carcinoma patients. Lee HJ; Cha HJ; Lim JS; Lee SH; Song SY; Kim H; Hancock WS; Yoo JS; Paik YK J Proteome Res; 2014 May; 13(5):2328-38. PubMed ID: 24628331 [TBL] [Abstract][Full Text] [Related]
6. Topic model-based mass spectrometric data analysis in cancer biomarker discovery studies. Wang M; Tsai TH; Di Poto C; Ferrarini A; Yu G; Ressom HW BMC Genomics; 2016 Aug; 17 Suppl 4(Suppl 4):545. PubMed ID: 27535232 [TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Liu T; Xue R; Huang X; Zhang D; Dong L; Wu H; Shen X Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):542-50. PubMed ID: 21659380 [TBL] [Abstract][Full Text] [Related]
8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646 [TBL] [Abstract][Full Text] [Related]
9. Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. Levin Y; Schwarz E; Wang L; Leweke FM; Bahn S J Sep Sci; 2007 Sep; 30(14):2198-203. PubMed ID: 17668910 [TBL] [Abstract][Full Text] [Related]
10. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Na K; Lee EY; Lee HJ; Kim KY; Lee H; Jeong SK; Jeong AS; Cho SY; Kim SA; Song SY; Kim KS; Cho SW; Kim H; Paik YK Proteomics; 2009 Aug; 9(16):3989-99. PubMed ID: 19658107 [TBL] [Abstract][Full Text] [Related]
11. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Sun S; Lee NP; Poon RT; Fan ST; He QY; Lau GK; Luk JM Liver Int; 2007 Oct; 27(8):1021-38. PubMed ID: 17845530 [TBL] [Abstract][Full Text] [Related]
12. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study. Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433 [TBL] [Abstract][Full Text] [Related]
13. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. Ahn YH; Shin PM; Oh NR; Park GW; Kim H; Yoo JS J Proteomics; 2012 Sep; 75(17):5507-15. PubMed ID: 22789673 [TBL] [Abstract][Full Text] [Related]
14. Continuous sample deposition from reversed-phase liquid chromatography to tracks on a matrix-assisted laser desorption/ionization precoated target for the analysis of protein digests. Wall DB; Berger SJ; Finch JW; Cohen SA; Richardson K; Chapman R; Drabble D; Brown J; Gostick D Electrophoresis; 2002 Sep; 23(18):3193-204. PubMed ID: 12298091 [TBL] [Abstract][Full Text] [Related]
15. MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma. Lee JY; Kim JY; Cheon MH; Park GW; Ahn YH; Moon MH; Yoo JS J Proteomics; 2014 Feb; 98():206-17. PubMed ID: 24434586 [TBL] [Abstract][Full Text] [Related]
16. Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Terracciano R; Pasqua L; Casadonte F; Frascà S; Preianò M; Falcone D; Savino R Bioconjug Chem; 2009 May; 20(5):913-23. PubMed ID: 19338374 [TBL] [Abstract][Full Text] [Related]
17. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. Zeng X; Hood BL; Sun M; Conrads TP; Day RS; Weissfeld JL; Siegfried JM; Bigbee WL J Proteome Res; 2010 Dec; 9(12):6440-9. PubMed ID: 20931982 [TBL] [Abstract][Full Text] [Related]
18. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics. Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453 [TBL] [Abstract][Full Text] [Related]